Skip to main content
T

TIANJIN TIANYAO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 600488 ISIN · CNE000001840 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,252 across all filing types
Latest filing 2026-05-19 M&A Activity
Country CN China
Listing Shanghai Stock Exchange 600488

About TIANJIN TIANYAO PHARMACEUTICAL CO., LTD.

Tianjin Tianyao Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of corticosteroid APIs and finished pharmaceutical products. As a prominent global supplier, the company maintains a comprehensive product portfolio featuring dexamethasone, prednisone, methylprednisolone, and hydrocortisone series. Its manufacturing capabilities encompass a wide range of dosage forms, including tablets, injections, ointments, and creams. The company adheres to international quality standards, holding certifications such as US FDA and European CEP, which facilitate its presence in global markets. By leveraging advanced fermentation and synthesis technologies, it provides high-quality pharmaceutical ingredients and preparations to healthcare providers and industrial partners worldwide.

Recent filings

Filing Released Lang Actions
津药药业股份有限公司关于上海上实（集团）有限公司及上海上实投资发展有限公司拟公开征集上海琉璃光医药发展有限公司100%股权受让方的提示性公告
M&A Activity Classification · 82% confidence The document is an official preliminary announcement (“提示性公告”) by the company regarding Shanghai Shixi Group’s planned public solicitation of transferees for 100% of the equity of Shanghai Liuliguang Pharmaceutical Development via an exchange. This relates directly to a proposed equity transfer/merger and acquisition transaction. It is not merely a routine report publication or regulatory filing; it is an M&A activity announcement. Therefore, the correct category is M&A Activity (TAR).
2026-05-19 Chinese
津药药业股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 88% confidence The document is a regulatory announcement on the Shanghai Stock Exchange regarding an abnormal trading fluctuation (20% price deviation over three days), including self-inspection results, risk warnings, and Q1 financial highlights solely in the context of stock volatility. It does not constitute an earnings release, interim report, or other substantive report, but is a compliance disclosure required by exchange rules. Thus it falls under general regulatory filings.
2026-05-19 Chinese
津药药业股份有限公司股票交易异常波动公告
Regulatory Filings Classification · 85% confidence The document is a legally mandated announcement under Shanghai Stock Exchange rules regarding an abnormal stock price fluctuation (“股票交易异常波动公告”). It contains regulatory disclosures, risk warnings, and confirmation that no undisclosed material events exist. It is not a full financial report (10-K/IR), earnings release, or other specialized filing but a standard compliance announcement. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-05-12 Chinese
津药药业股份有限公司2025年度董事会审计风险控制委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2025年度董事会审计与风险控制委员会履职情况报告" which translates to "2025 Annual Report on the Performance of the Board Audit and Risk Control Committee." It details the committee's activities, meetings, supervision of external auditors, internal audit guidance, internal control evaluation, review of financial reports, and coordination with management and auditors. The document is a detailed report on the committee's work and oversight functions rather than a simple announcement or certification. It does not contain full financial statements but focuses on audit and risk control committee activities and their oversight role. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and related oversight information. The document length is 3365 characters, which is relatively short but contains substantive content about audit committee activities, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2025
2026-04-24 Chinese
津药药业股份有限公司第九届董事会第二十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 26th meeting of the 9th Board of Directors of the company, including approval of various reports such as the 2025 Annual Report, 2025 Annual Financial Statements, Profit Distribution Plan, Sustainability Report, Internal Control Evaluation Report, and other related reports. It also mentions that these reports and detailed contents are available on the Shanghai Stock Exchange website, indicating that the document itself is not the full annual report but a board meeting resolution announcement. The document is about board decisions and approvals, not the full financial report or earnings release. The document length is 4331 characters, which is relatively short and mostly a summary of board resolutions. Therefore, it fits best under the category of Board/Management Information (MANG), as it announces board meeting decisions and approvals related to management and governance matters.
2026-04-24 Chinese
津药药业股份有限公司2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "津药药业股份有限公司2026年第一季度报告" which translates to "Jinyao Pharmaceutical Co., Ltd. 2026 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on non-recurring gains and losses. The report covers the first quarter of 2026, indicating it is a quarterly financial report. The document length is over 14,000 characters, and it includes substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-24 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.